EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomised controlled trial

Muzhda Ghanizada, Sofia Malm Tillgren, Mandy Menzel, Louis Praeger-Jahnsen, Nihaya Mahmoud Said, Sisse Ditlev iD, Asger Sverrild, Celeste Porsbjerg, Lena Uller, Therese Lapperre iD, AZIMUNE Study Group

European Respiratory Journal · 2026

DOI: 10.1183/13993003.02441-2025 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2026. Verfasst von Muzhda Ghanizada und 10 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Research Unit, Department of Respiratory and Infectious Diseases, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark muzhda.ghani…. Hauptthemen laut MEDLINE: Azithromycin, Asthma, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Forskningsrådet om Hälsa, Arbetsliv och Välfärd, Swedish Heart and Lung Foundation, Novo Holdings.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Viral respiratory infections are the leading trigger of asthma exacerbations, and impaired epithelial type I and III interferon (IFN) responses may contribute to more severe exacerbations. Azithromycin reduces exacerbations clinically, but its effects on epithelial antiviral immunity remain unclear. This study investigated whether azithromycin treatment enhances airway epithelial antiviral responses and modulates alarmin concentrations in patients with uncontrolled asthma.

Methods

In the investigator-initiated, double-blind, placebo-controlled AZIMUNE trial, 40 adults with uncontrolled asthma were randomised (1:1) to azithromycin (500 mg three times per week) or placebo (identical regimen) for 12 weeks. Bronchial epithelial cells were obtained via bronchoscopy at baseline and after week 12, and cultured and infected ex vivo with rhinovirus. Protein levels of IFN-β, IFN-λ, alarmins (interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP)) and pro-inflammatory cytokines were quantified.

Results

Azithromycin significantly increased rhinovirus-induced concentrations of IFN-β (p=0.047) and IFN-λ (p=0.013) in the azithromycin group (n=16) compared with baseline, whereas no change was seen in the placebo group (n=16). Azithromycin treatment also reduced IL-33 concentrations (p=0.001), while TSLP levels were unaffected. Clinical outcomes improved numerically in the azithromycin group, but differences versus placebo were not statistically significant.

Conclusions

Azithromycin enhances epithelial antiviral immunity and attenuates IL-33 concentrations in response to rhinoviral infection in asthma. The dual immunomodulatory effect of azithromycin supports its role as adjunctive therapy to prevent virus-induced exacerbations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinAsthmaAntiviral AgentsHumansFemaleMaleDouble-Blind MethodAdultMiddle AgedCytokinesRhinovirusEpithelial CellsInterferon-betaInterleukin-33Thymic Stromal LymphopoietinInterferon LambdaInterferonsBronchoscopyInterleukins

Substanzen

AzithromycinCytokinesInterferon-betaInterleukin-33Antiviral AgentsThymic Stromal LymphopoietinInterferon LambdaIL33 protein, humanInterferonsinterferon-lambda, human

Autor:innen und Institutionen

  • Respiratory Research Unit, Department of Respiratory and Infectious Diseases, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark muzhda.ghanizada.02@regionh.dk.
  • Unit of Respiratory Immunopharmacology, Department of Experimental Medical Science, Lund University, Lund, Sweden.
  • Copenhagen Centre for Translational Research, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
  • Respiratory Research Unit, Department of Respiratory and Infectious Diseases, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Shared last authorship.

ORCID-Profile: Sisse Ditlev, Therese Lapperre

Förderung

  • Forskningsrådet om Hälsa, Arbetsliv och Välfärd
  • Swedish Heart and Lung Foundation
  • Novo Holdings

Zitieren

APA

Ghanizada, M., Malm Tillgren, S., Menzel, M., Praeger-Jahnsen, L., Said, N. M., Ditlev, S., Sverrild, A., Porsbjerg, C., Uller, L., Lapperre, T., & AZIMUNE Study Group (2026). Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomised controlled trial. European Respiratory Journal. https://doi.org/10.1183/13993003.02441-2025

Vancouver

Ghanizada M, Malm Tillgren S, Menzel M, Praeger-Jahnsen L, Said NM, Ditlev S, et al. Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomised controlled trial. European Respiratory Journal. 2026. doi:10.1183/13993003.02441-2025

BibTeX
@article{Ghanizada2026,
  author = {Ghanizada, Muzhda and Malm Tillgren, Sofia and Menzel, Mandy and Praeger-Jahnsen, Louis and Said, Nihaya Mahmoud and Ditlev, Sisse and Sverrild, Asger and Porsbjerg, Celeste and Uller, Lena and Lapperre, Therese and AZIMUNE Study Group, AZIMUNE Study Group},
  title = {Azithromycin enhances epithelial antiviral immunity in uncontrolled asthma: results from the AZIMUNE randomised controlled trial},
  journal = {European Respiratory Journal},
  year = {2026},
  doi = {10.1183/13993003.02441-2025}
}
Kostenlos starten →